[Federal Register Volume 65, Number 229 (Tuesday, November 28, 2000)]
[Notices]
[Page 70937]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-30291]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated September 1, 2000, and published in the Federal 
Register on September 25, 2000, (65 FR 57621), Glaxo Wellcome Inc., 
Attn: Jeffrey A. Weiss, 1011 North Avendell Avenue, P.O. Box 1217, 
Zebulon, North Carolina 27597-2309, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as an importer 
of remifentanil (9739), a basic class of controlled substance listed in 
Schedule II.
    The remifentanil is being imported for the production of Ultiva 
dosage forms and for research and new product development.
    No comments or objections have been received. DEA has considered 
the factors in title 21, United States Code, section 823(a) and 
determined that the registration of Glaxo Wellcome Inc. to import 
remifentanil is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. DEA has investigated 
Glaxo Wellcome Inc. on a regular basis to ensure that the company's 
continued registration is consistent with the public interest. These 
investigations have included inspection and testing of the company's 
physical security systems, audits of the company's records, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to section 1008(a) of the Controlled Substances Import and Export Act 
and in accordance with title 21, Code of Federal Regulations, section 
1301.34, the above firm is granted registration as an importer of the 
basic class of controlled substance listed above.

    Dated: November 7, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 00-30291 Filed 11-27-00; 8:45 am]
BILLING CODE 4410-09-M